Med. praxi. 2023;20(4):201-210 | DOI: 10.36290/med.2023.034

Rheumatoid arthritis - diagnosis and treatment

prof. MUDr. Petr Němec, Ph.D.
Revmatologická ambulance II. interní kliniky FN u sv. Anny v Brně a LF MU, Brno

Rheumatoid arthritis is a severe chronic autoimmune inflammatory disease affecting 0.5-1% of the population, with a predominance of middle-aged women. Typical symptoms of the disease include pain and stiffness, especially in the small joints of the hands or feet, predominating in the morning, and fatigue. Chronic inflammation of the joints results in structural damage with significant impairment of physical and occupational abilities and impaired quality of life. Extra-articular manifestations of the disease and comorbidities may increase mortality. The diagnosis of rheumatoid arthritis can be established based on a well-taken medical history, and clinical examination with the contribution of laboratory and imaging methods. Current classification criteria may be helpful. The basic principles of rheumatoid arthritis treatment include its early initiation immediately after diagnosis and the choice of an appropriate treatment strategy aimed at achieving and long-term maintaining therapeutic goals. Decisions on treatment strategy should be based on an assessment of disease activity, safety of treatment, and other factors such as the presence of comorbidities and progression of structural damage, and should take into account the patient's preferences as well as the costs associated with treatment. Treatment must be comprehensive, however, pharmacotherapy using disease-modifying antirheumatic drugs is pivotal. Given the chronic and heterogeneous course of the disease, patients may require access to multiple treatment strategies and medications over the course of their lives. General practitioners can make a significant contribution to the early diagnosis of rheumatoid arthritis if they refer patients with clinically suspected disease, with arthritis of at least one of the metacarpophalangeal or metatarsophalangeal joints, to a specialist rheumatology unit promptly, optimally after individual discussion with a rheumatologist.

Keywords: arthritis, diagnostics, rheumatoid, therapy.

Accepted: May 11, 2023; Published: September 26, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Němec P. Rheumatoid arthritis - diagnosis and treatment. Med. praxi. 2023;20(4):201-210. doi: 10.36290/med.2023.034.
Download citation

References

  1. Němec P. Revmatoidní artritida. In: Němec, et al. Revmatologie pro praxi. Praha: Grada Publishing; 2021.
  2. Løgstrup BB, Ellingsen T, Pedersen AB, et al. Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population. Rheumatology (Oxford). 2021;60:1400. Go to original source... Go to PubMed...
  3. Yamamoto K, Okada Y, Suzuki A, et al. Genetic studies of rheumatoid arthritis. Proc Jpn Acad Ser B Phys Biol Sci. 2015;91:410-22. Go to original source... Go to PubMed...
  4. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum, DiS. 2010;69:1580-8. Go to original source... Go to PubMed...
  5. Van Steenbergen HW, Aletaha D, Beaart­‑van de Voorde LJ, et al. Extended report: EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum, DiS. 2017;76:491-496. Go to original source... Go to PubMed...
  6. Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum, DiS. 2013;72:804-14. Go to original source... Go to PubMed...
  7. Van der Heijde D, van der Helm­‑van Mil AH, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum, DiS. 2013;72:479-81. Go to original source... Go to PubMed...
  8. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Ann Rheum, DiS. 2011;70:404-413. Go to original source... Go to PubMed...
  9. Mann H. Revmatoidní artritida. In: Šenolt L, Mann H, Závada J. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře, revmatologie, novelizace 2021. Společnost všeobecného lékařství ČLS JEP, Centrum doporučených postupů pro praktické lékaře [Internet]. Available from: https://www.svl.cz/files/files/Doporucene­‑postupy/2020/DP­‑Revma.pdf, ISBN 978-80-88280-29-3.
  10. Klinkhoff A. Rheumatology: 5. Diagnosis and management of inflammatory polyarthritis. CMAJ. 2000;162:1833-1838.
  11. Smolen JS, Landewé R, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease­‑modifying antirheumatic drugs: 2022 update. Ann Rheum, DiS. 2023;82(1):3-18. Go to original source... Go to PubMed...
  12. Šenolt L, Mann H, Závada J, et al. Doporučení České revmatologické společnosti pro farmakologickou léčbu revmatoidní artritidy 2017. Čes Revmatol. 2017;25:8-24.
  13. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of rheumatology Guideline fot the treatment of rheumatoid arthritis. Arthritis Rehum. 2021;73(7):1108-1123. Go to original source... Go to PubMed...
  14. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease­‑modifying antirheumatic drugs. Ann Rheum, DiS. 2014;73:3-5. Go to original source... Go to PubMed...
  15. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum, DiS. 2016;75:3-15. Go to original source... Go to PubMed...
  16. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386:316-326. Go to original source... Go to PubMed...
  17. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. Available from: https://www.ema.europa.eu/en/news/ema­‑recommends­‑measures­‑minimise­‑risk­‑serious­‑side­‑effects­‑janus­‑kinase­‑inhibitors­‑chronic.
  18. Procházková L. Antirevmatické léky v těhotenství a laktaci. In: Němec, et al. Revmatologie pro praxi. Praha: Grada Publishing; 2021.
  19. Roman R. Vakcinace u pacientů s revmatickým onemocněním. In: Němec, et al. Revmatologie pro praxi. Praha: Grada Publishing; 2021.
  20. Běhounek J, Sedláčková M. Základy rehabilitace pacienta s revmatickým onemocněním. In: Němec, et al. Revmatologie pro praxi. Praha: Grada Publishing; 2021.




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.